Progenics Pharmaceuticals, Inc.' Data From a Phase 1 Study of PSMA ADC Presented at American Society of Clinical Oncology 2013

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TARRYTOWN, N.Y., June 1, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Two additional abstracts related to PSMA ADC also were selected for publication in the ASCO Annual Meeting Proceedings.

Help employers find you! Check out all the jobs and post your resume.

Back to news